Aims: The aim of this study was to determine the mechanisms of atrial fibrillation (AF) in patients with left ventricular systolic dysfunction (LVSD).
Methods And Results: Dominant frequency (DF) spatiotemporal stability was studied in 15 patients with persistent AF (PEAF) and LVSD (Group I), 15 with PEAF without LVSD (Group II), and 10 with paroxysmal AF (PAAF) without LVSD (Group III). Dominant frequencies were analysed at 536 sites at baseline (DF1) and 26 +/- 12 min later (DF2). A DF1-DF2 difference of
Conclusion: Dominant frequency stability supports stable arrhythmia sources as the mechanism of PEAF with (without) LVSD, but not of PAAF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/europace/eup053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Subclinical left ventricular dysfunction in rheumatoid arthritis: findings from the prospective Porto-RA cohort.
Clin Res Cardiol
September 2024
Department of Cardiology, Unidade Local de Saúde de Santo António, Largo Do Prof. Abel Salazar, 4099-001, Porto, Portugal.
Aim: Patients with rheumatoid arthritis (RA) have an increased risk of cardiac dysfunction and heart failure (HF) due to a pro-inflammatory state. Detecting cardiac dysfunction in RA is challenging as these patients often present preserved ejection fraction (EF) but may have subclinical ventricular dysfunction. Echocardiographic strain analysis is a promising tool for early detection of subclinical left ventricular systolic dysfunction (LVSD).
View Article and Find Full Text PDFPrognostic impact of diagnosis-to-ablation time on outcomes following catheter ablation in persistent atrial fibrillation and left ventricular systolic dysfunction.
Heart Rhythm
September 2024
Baker Heart and Diabetes Institute, Melbourne, Australia; The Alfred Hospital, Melbourne, Australia; University of Melbourne, Melbourne, Australia; Monash University, Melbourne Australia. Electronic address:
Article Synopsis
- The study investigates the effect of the time from atrial fibrillation (AF) diagnosis to catheter ablation (DAT) on outcomes for patients with both AF and left ventricular systolic dysfunction (LVSD).
- Results show that a shorter DAT (less than 1 year) leads to better clinical outcomes, including higher rates of being free from arrhythmias and improved left ventricular ejection fraction (LVEF) after 12 months.
- The findings suggest that earlier catheter ablation in patients with AF and LVSD is linked to fewer hospitalizations and a better overall prognosis.
Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial.
Circulation
November 2024
M3C-Necker, Congenital and Paediatric Cardiology Department, Hospital Necker-Enfants Malades, University of Paris Cité, France (D.B.).
Background: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction. It has not been rigorously compared with angiotensin-converting enzyme inhibitors in children. PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) is a randomized, double-blind trial that evaluated the pharmacokinetics and pharmacodynamics (PK/PD), safety, and efficacy of sacubitril/valsartan versus enalapril in children 1 month to <18 years of age with HF attributable to systemic left ventricular systolic dysfunction (LVSD).
View Article and Find Full Text PDFPredictive model for left main coronary artery or triple vessel disease in patients with chronic coronary syndromes.
Asian Biomed (Res Rev News)
August 2024
Department of Cardiology, Central Chest Institute of Thailand, Nonthaburi 11000, Thailand.
Background: Data about prediction of left main coronary artery disease (LMCAD)/three-vessel disease (TVD) in patients with chronic coronary syndromes (CCS) are lacking.
Objectives: This study aimed to develop a model for predicting patients at risk of LMCAD/TVD.
Methods: This study used retrospective data from patients with CCS scheduled for invasive coronary angiography (ICA) and who were retrospectively recruited between January 2018 and December 2020.
The protective effect of Ghrelin peptide on doxorubicin hydrochloride induced heart failure in rats.
J Cardiothorac Surg
September 2024
Department of Cardiology, Jiangxi Provincial People's Hospital, the First Affiliated Hospital of Nanchang Medical College, Nanchang, 330006, Jiangxi Province, China.
Background: To investigate the protective effect and mechanism of Ghrelin on Doxorubicin (Dox) hydrochloride induced heart failure (HF) and myocardial injury in rats.
Methods: 45 rats were randomly divided into control group, HF group and Ghrelin group. Dox hydrochloride was injected intraperitoneally to establish the model of HF in rats of HF group and Ghrelin group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!